España
India
Italia
대한민국
日本
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Glaukos
GKOS
NYSE
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$156.44
-1.31
-0.83%
At close: -
$156.00
-0.44
-0.28%
After Hours: Jan 31, 7:26 PM EDT
Get Report
Comment
Glaukos (GKOS) Forecast
News
Earnings
Glaukos (GKOS) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Glaukos (NYSE:GKOS) Stock
Glaukos Stock (NYSE: GKOS)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Monday, January 27, 2025
Piper Sandler Reiterates Overweight on Glauko...
Benzinga Newsdesk
How Is The Market Feeling About Glaukos?
Benzinga Insights
Thursday, January 23, 2025
$1000 Invested In Glaukos 5 Years Ago Would Be Worth This Much Today
Benzinga Insights
Tuesday, January 14, 2025
Glaukos Announces Clinical Updates For iDose ...
Benzinga Newsdesk
Monday, January 13, 2025
Short Seller Accuses TransMedics Of 'Mafia Style' Scheme, Organ Transplant Company Says Short Seller Manipulating Market
Vandana Singh
Tuesday, December 31, 2024
What 11 Analyst Ratings Have To Say About Glaukos
Benzinga Insights
Glaukos To Rally Around 17%? Here Are 6 Top Analyst Forecasts For Tuesday
Avi Kapoor
Stifel Maintains Buy on Glaukos, Raises Price...
Benzinga Newsdesk
Thursday, December 26, 2024
(GKOS) - Analyzing Glaukos's Short Interest
Benzinga Insights
Monday, December 23, 2024
Glaukos Seeks FDA Approval for Non-Invasive K...
Benzinga Newsdesk
Wednesday, December 18, 2024
Truist Securities Maintains Buy on Glaukos, R...
Benzinga Newsdesk
Wednesday, December 11, 2024
Glaukos shares are trading higher after Citig...
Benzinga Newsdesk
Wells Fargo Maintains Overweight on Glaukos, ...
Benzinga Newsdesk
Citigroup Upgrades Glaukos to Buy, Raises Pri...
Benzinga Newsdesk
Friday, December 06, 2024
This Constellation Brands Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Avi Kapoor
UBS Initiates Coverage On Glaukos with Buy Ra...
Benzinga Newsdesk
Tuesday, December 03, 2024
How Is The Market Feeling About Glaukos?
Benzinga Insights
Monday, December 02, 2024
Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos
Vandana Singh
Stifel Maintains Buy on Glaukos, Raises Price...
Benzinga Newsdesk
This Kohl's Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
Avi Kapoor
Morgan Stanley Downgrades Glaukos to Underwei...
Benzinga Newsdesk
Tuesday, November 26, 2024
Analyst Scoreboard: 5 Ratings For Glaukos
Benzinga Insights
BTIG Maintains Buy on Glaukos, Raises Price T...
Benzinga Newsdesk
Tuesday, November 05, 2024
Glaukos Reports 30% Boost In Glaucoma Sales, Improved Margins In Q3, Analyst Highlights Certain Headwinds
Vandana Singh
JP Morgan Maintains Overweight on Glaukos, Ra...
Benzinga Newsdesk
Wells Fargo Maintains Overweight on Glaukos, ...
Benzinga Newsdesk
Monday, November 04, 2024
Glaukos shares are trading lower. The company...
Benzinga Newsdesk
Glaukos Sees 2024 Net Sales $377M-$379M
Benzinga Newsdesk
Glaukos Q3 2024 Adj. EPS $(0.28) Beats $(0.48...
Benzinga Newsdesk
Wednesday, October 30, 2024
How Is The Market Feeling About Glaukos?
Benzinga Insights
Wednesday, October 16, 2024
Glaukos Says Phase 3 Confirmatory Trial Of Ep...
Benzinga Newsdesk
Monday, October 14, 2024
A Closer Look at 7 Analyst Recommendations For Glaukos
Benzinga Insights
Truist Securities Maintains Buy on Glaukos, R...
Benzinga Newsdesk
Wednesday, September 11, 2024
Glaukos Stocks Rides on Strong Product Demand Amid Competition
Zacks
Tuesday, September 03, 2024
Stifel Maintains Buy on Glaukos, Raises Price...
Benzinga Newsdesk
Wednesday, August 28, 2024
Navigating 11 Analyst Ratings For Glaukos
Benzinga Insights
BTIG Maintains Buy on Glaukos, Raises Price T...
Benzinga Newsdesk
Thursday, August 01, 2024
Glaukos Stock: A Deep Dive Into Analyst Perspectives (12 Ratings)
Benzinga Insights
Glaukos Q2 Earnings In Line, Glaucoma Drives Sales
Zacks
Piper Sandler Maintains Overweight on Glaukos...
Benzinga Newsdesk
Wells Fargo Maintains Overweight on Glaukos, ...
Benzinga Newsdesk
Truist Securities Reiterates Buy on Glaukos, ...
Benzinga Newsdesk
Meta To Rally Around 35%? Here Are 10 Top Analyst Forecasts For Thursday
Avi Kapoor
Needham Maintains Buy on Glaukos, Raises Pric...
Benzinga Newsdesk
Wednesday, July 31, 2024
Glaukos Sees FY24 Revenue $370M-$376M Vs $363...
Benzinga Newsdesk
Glaukos Q2 Adj $(0.52), Inline, Sales $95.69M...
Benzinga Newsdesk
Wednesday, July 17, 2024
Will WATCHMAN Sales Aid Boston Scientific's Q2 Earnings?
Zacks
Tuesday, July 16, 2024
Truist Securities Maintains Buy on Glaukos, R...
Benzinga Newsdesk
Monday, July 15, 2024
BTIG Maintains Buy on Glaukos, Raises Price T...
Benzinga Newsdesk
Morgan Stanley Maintains Equal-Weight on Glau...
Benzinga Newsdesk
Show More